Development of lipid-core-peptide (LCP) based vaccines for the prevention of the group A streptococcal (GAS) infection

Moyle, P. M., Horvath, A., Olive, C., Good, M. F. and Toth, I. (2003) Development of lipid-core-peptide (LCP) based vaccines for the prevention of the group A streptococcal (GAS) infection. Letters In Peptide Science, 10 5-6: 605-613. doi:10.1007/BF02442594

Author Moyle, P. M.
Horvath, A.
Olive, C.
Good, M. F.
Toth, I.
Title Development of lipid-core-peptide (LCP) based vaccines for the prevention of the group A streptococcal (GAS) infection
Journal name Letters In Peptide Science   Check publisher's open access policy
ISSN 0929-5666
Publication date 2003-09
Year available 2004
Sub-type Article (original research)
DOI 10.1007/BF02442594
Volume 10
Issue 5-6
Start page 605
End page 613
Total pages 9
Place of publication Leiden, Netherlands
Publisher Springer
Collection year 2004
Language eng
Subject C1
250399 Organic Chemistry not elsewhere classified
780103 Chemical sciences
0399 Other Chemical Sciences
Abstract Traditional vaccines consisting of whole attenuated micro-organisms. or microbial components administered with adjuvant, have been demonstrated as one of the most cost-effective and successful public health interventions. Their use in large scale immunisation programs has lead to the eradication of smallpox, reduced morbidity and mortality from many once common diseases, and reduced strain on health services. However, problems associated with these vaccines including risk of infection. adverse effects, and the requirement for refrigerated transport and storage have led to the investigation of alternative vaccine technologies. Peptide vaccines, consisting of either whole proteins or individual peptide epitopes, have attracted much interest, as they may be synthesised to high purity and induce highly specific immune responses. However, problems including difficulties stimulating long lasting immunity. and population MHC diversity necessitating multiepitopic vaccines and/or HLA tissue typing of patients complicate their development. Furthermore, toxic adjuvants are necessary to render them immunogenic. and as such non-toxic human-compatible adjuvants need to be developed. Lipidation has been demonstrated as a human compatible adjuvant for peptide vaccines. The lipid-core-peptide (LCP) system. incorporating lipid adjuvant, carrier, and peptide epitopes, exhibits promise as a lipid-based peptide vaccine adjuvant. The studies reviewed herein investigate the use of the LCP system for developing vaccines to protect against group A streptococcal (GAS) infection. The studies demonstrate that LCP-based GAS vaccines are capable of inducing high-titres of antigen specific IgG antibodies. Furthermore. mice immunised with an LCP-based GAS vaccine were protected against challenge with 8830 strain GAS.
Keyword Biochemistry & Molecular Biology
group A streptococci (GAS)
lipid-core-peptide (LCP) system
peptide vaccines
vaccine adjuvants
Rheumatic Heart-disease
Borrelia-burgdorferi Lipoproteins
T-cell Responses
Lipopeptide Vaccine
Conserved Region
Carrier System
Q-Index Code C1
Additional Notes Journal published in 2004 and backdated

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
2005 Higher Education Research Data Collection
School of Pharmacy Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 6 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 10 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 15 Aug 2007, 04:02:51 EST